Danaher Corp
DHRQ2 2025(DHR Q1 FY2025)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$805.4M
AI Revenue (Q)
$58.0M
Total Revenue (Q)
$5.8B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q1 FY2025 (three-month period ended March 28, 2025). Total sales $5,741M. Segments: Biotechnology $1,612M, Life Sciences $1,680M, Diagnostics $2,449M. No AI revenue disclosure. DHR divested a product line in Diagnostics generating ~$50M annual revenue but this was unrelated to AI. No AI-specific disclosures. Conservative 1% for embedded instrument algorithms. Math: ~$57M estimated / $5,741M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $5,741 [three-month period ended March 28, 2025]
10-Q Q1 FY2025, Consolidated Condensed Statements of Earnings
Biotechnology $1,612; Life Sciences $1,680; Diagnostics $2,449 [three-month period ended March 28, 2025]
10-Q Q1 FY2025, Note 5 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix